Olumiant (baricitinib)

pCPA File Number: 21159
Negotiation Status:
Concluded with an LOI
Indication(s):
Subacute and chronic inflammatory joint diseases
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CADTH Project Number:
SR0597-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: